RCS - Feedback PLC - UK Medical Device Certification for Bleepa

FeedbackAnnouncement

29/06/2021 07:05

RNS Number : 3912D
  
Feedback PLC
  
29 June 2021
  
 

Reach announcement
 
Feedback plc
 
Bleepa affixed with a UK Medical Device Certification (UKCA)
 
·      UKCA regulatory certification further validates Bleepa technology
 
London, 29 June 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that a UKCA mark, the post-BREXIT UK regulatory certification, has been affixed to Bleepa, Feedback's flagship medical imaging communications platform, adding to its portfolio of regulatory approvals for Bleepa.
 
Dr Tom Oakley, CEO of Feedback, commented:
 
"In addition to the CE mark affixed last year, Bleepa has now enhanced its regulatory technical file to include the UK's medical Device Manufacturing mark.  The new UK product marking is used for goods being placed on the market in Great Britain post-BREXIT and further validates as well as provides confidence in the quality and expertise of Bleepa's technology."
 
Enquiries:
 



Feedback plc
Tom Oakley, CEO
 
Feedback media:
Nick Mayhew, Chief Marketing Lead


+44 (0)1954 718072
IR@fbk.com
 
 
+44 (0) 7736 065353














Allenby Capital Limited (Nominated Adviser)
David Worlidge / Vivek Bhardwaj


+44 (0)20 3328 5656














Peterhouse Capital Limited (Joint Broker)
Lucy Williams / Duncan Vasey


+44 (0)20 7469 0936














Stanford Capital Partners Limited (Joint Broker)
Patrick Claridge / John Howes


+44 20 3815 8880














Walbrook PR Ltd


Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 




Paul McManus/Nick Rome/Nicholas Johnson


07980 541 893 or 07748 325 236 or 07884 664 686



 
 
Notes to Editors
 
Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.  
 
Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.
 
About Reach announcements
 
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAFLFIDRSITFIL